GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Perspective Therapeutics Inc (AMEX:CATX) » Definitions » Cyclically Adjusted Revenue per Share

Perspective Therapeutics (Perspective Therapeutics) Cyclically Adjusted Revenue per Share : $0.00 (As of Mar. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Perspective Therapeutics Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Perspective Therapeutics's adjusted revenue per share for the three months ended in Mar. 2024 was $0.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.00 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -5.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -7.00% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was -8.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Perspective Therapeutics was 2.70% per year. The lowest was -10.60% per year. And the median was -4.90% per year.

As of today (2024-05-23), Perspective Therapeutics's current stock price is $1.51. Perspective Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $0.00. Perspective Therapeutics's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Perspective Therapeutics was 17.23. The lowest was 1.71. And the median was 3.38.


Perspective Therapeutics Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Perspective Therapeutics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Perspective Therapeutics Cyclically Adjusted Revenue per Share Chart

Perspective Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.15 0.13 0.13 0.12 0.11

Perspective Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.12 0.11 0.11 -

Competitive Comparison of Perspective Therapeutics's Cyclically Adjusted Revenue per Share

For the Medical Devices subindustry, Perspective Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Perspective Therapeutics's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Perspective Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Perspective Therapeutics's Cyclically Adjusted PS Ratio falls into.



Perspective Therapeutics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Perspective Therapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0/131.7762*131.7762
=0.000

Current CPI (Mar. 2024) = 131.7762.

Perspective Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.018 100.560 0.024
201409 0.019 100.428 0.025
201412 0.019 99.070 0.025
201503 0.021 99.621 0.028
201506 0.024 100.684 0.031
201509 0.023 100.392 0.030
201512 0.022 99.792 0.029
201603 0.022 100.470 0.029
201606 0.020 101.688 0.026
201609 0.020 101.861 0.026
201612 0.019 101.863 0.025
201703 0.023 102.862 0.029
201706 0.025 103.349 0.032
201709 0.022 104.136 0.028
201712 0.028 104.011 0.035
201803 0.029 105.290 0.036
201806 0.029 106.317 0.036
201809 0.024 106.507 0.030
201812 0.028 105.998 0.035
201903 0.029 107.251 0.036
201906 0.029 108.070 0.035
201909 0.034 108.329 0.041
201912 0.033 108.420 0.040
202003 0.043 108.902 0.052
202006 0.033 108.767 0.040
202009 0.035 109.815 0.042
202012 0.028 109.897 0.034
202103 0.021 111.754 0.025
202106 0.019 114.631 0.022
202109 0.018 115.734 0.020
202112 0.020 117.630 0.022
202203 0.020 121.301 0.022
202206 0.018 125.017 0.019
202209 0.012 125.227 0.013
202212 0.013 125.222 0.014
202303 0.000 127.348 0.000
202306 0.005 128.729 0.005
202309 0.007 129.860 0.007
202312 -0.019 129.419 -0.019
202403 0.000 131.776 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Perspective Therapeutics  (AMEX:CATX) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Perspective Therapeutics was 17.23. The lowest was 1.71. And the median was 3.38.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Perspective Therapeutics Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Perspective Therapeutics's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Perspective Therapeutics (Perspective Therapeutics) Business Description

Traded in Other Exchanges
Address
350 Hills Street, Suite 106, Richland, WA, USA, 99354
Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body. The Company operates two reportable business segments: Brachytherapy and Drug Operations. It is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes.
Executives
Williamson Robert F Iii director 140 LASALLE AVENUE, PIEDMONT CA 94610
Markus Puhlmann officer: Chief Medical Officer 350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Jonathan Robert Hunt officer: Chief Financial Officer 350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Lori A Woods officer: Vice President 350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Heidi Henson director 2173 SALK AVENUE, SUITE 250, PMB#052, CARLSBAD CA 92008
Frank Morich director 40 GUEST STREET, BOSTON MA 02135
Johan M. Spoor director, officer: CEO 500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116
Mark John Austin officer: Controller/Prin Fin&Acct Offic 350 HILLS ST, STE 106, RICHLAND WA 99354
Philip J Vitale director 8849 E. CALLE DE LAS BRISAS, SCOTTSDALE AZ 85255
Michael W Mccormick director 9923 EAST BELL ROAD, STE 130, SCOTTSDALE AZ 85260
William Cavanagh officer: Vice President 350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Alan Hoffmann director 3030 EAST CACTUS ROAD, SUITE 101, PHOENIX AZ 85032
Michael Krachon officer: VP of Sales & Marketing 350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Krista Cline officer: Dir. of Operations, Secretary 350 HILLS STREET, STE 106, RICHLAND WA 99354
Jennifer Streeter officer: VP of Human Resources 350 HILLS STREET SUITE 106, RICHLAND WA 99354

Perspective Therapeutics (Perspective Therapeutics) Headlines